We look for and find great opportunities
Blackhawk Growth Corp. is an investment issuer looking to capitalize on market and industry trends that can create substantial value for its shareholders. We look for opportunities all over the globe where we can leverage our knowledge, expertise, and experience to deliver substantial growth for our companies and our investors.
Blackhawk drives its growth by investing in equity and debt instruments of companies and generating positive returns with minimal risk for shareholders. The company’s strategy is focused on investing in multiple companies across a variety of sectors across North America.
Blackhawk signed a definitive agreement with Medigen Biotechnology Corporation and TBG Biotechnology Corp. to distribute certain diagnostic products, including an ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit used in the detection of antibodies associated with COVID-19. Both testing kits are EUA approved by the FDA.
Vancouver, British Columbia - TheNewswire - October 19, 2020 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (the "Corporation" or "Blackhawk"), is pleased to provide the following corporate update. The Health Canada Interim Order ("IO") application was completed and submitted for the ExProbe SARS-CoV-2 Testing Kit. The Company received confirmation of receipt from Health Canada on October 14, 2020. Even though Blackhawk…
Vancouver, British Columbia - TheNewswire - October 16, 2020 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) US (OTC:BLRZF) (the "Company"), is pleased to announce that it has acquired (the "Transaction") all of the outstanding share capital of Trip Pharma Inc. ("Trip Pharma"). Led by Dr. Krista Leicht, Trip Pharma is a privately-held arms-length psychedelic development and wellness company based in…